Emmes Strengthens Government Sector with New Leadership Role to Drive Innovation

Emmes Expands Its Government Business Footprint

Emmes, a prominent tech-forward Contract Research Organization (CRO), has made a significant strategic move by appointing Bryan Patterson as its new Senior Vice President of Government Business Development. This position, newly created, signifies Emmes' commitment to fortifying its footprint in government-sponsored clinical research efforts.

A Strong Leader for Government Initiatives

With an extensive career spanning over 14 years focused on securing new clinical research programs and building strategic partnerships with U.S. Federal Government agencies, Patterson brings a wealth of experience to the table. His previous roles at notable organizations like PPD and Rho underscore his ability to nurture strong collaborations, making him the ideal candidate to lead this new chapter.

Paul VanVeldhuisen, the President of Emmes Public Sector, will oversee Patterson’s work, highlighting how essential this new appointment is for the growth of Emmes' government business portfolio. As Patterson settles into this role, his primary aim will be to enhance partnerships and develop innovative solutions tailored for government-sponsored clinical trials.

Transforming Clinical Research

Patterson's career has been marked by a commitment to innovation and excellence. Emmes' CEO, Peter Ronco, expressed his excitement about Patterson joining the organization during this transformative era for clinical research, emphasizing the value Patterson's leadership will bring. The company is dedicated to integrating advanced technology and artificial intelligence into its clinical research methodologies, reinforcing its position as a leader in the field.

In his statement, Patterson conveyed his enthusiasm for the new role, acknowledging the critical period Emmes is navigating and how he aims to leverage his experience to enhance the company’s impact. The focus on merging deep scientific knowledge with AI-driven solutions is crucial for accelerating medical breakthroughs in government-related health initiatives.

Emmes' Vision for the Future

Originally founded over 47 years ago, Emmes has continually evolved, establishing itself as a key clinical research provider for U.S. federal agencies. The organization is dedicated not only to government contracts but also to public-private partnerships and the biopharma sector. In a rapidly changing landscape, where innovation is paramount, Emmes strives to redefine how government-sponsored research is conducted.

As the landscape of clinical research continues to shift, Emmes aims to streamline processes, thereby improving efficiency and efficacy in delivering vital health solutions. Patterson’s role will be central in navigating this complex environment, focusing on opportunities that will set a new standard for clinical research collaboration in the public sector.

About Emmes Group

Emmes is a full-service global CRO, wholly owned by New Mountain Capital, that emphasizes not just research but the very development of new medical treatments and public health advancements. With a portfolio that boasts over 2,000 clinical trials executed across a multitude of agencies, Emmes is best known for its prowess in sectors like cell and gene therapy, vaccines, and infectious diseases. The company uses a blend of human and artificial intelligence to optimize the research processes, distinguishing itself as a leader in the ever-evolving health landscape.

For anyone interested in learning more about Emmes and its innovative approaches to clinical research, visit www.emmes.com for more information.